UTHR (STOCKS)
United Therapeutics Corp
$501.270000
-10.450000 (-2.04%)
Prev close: $511.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $21,495.96M
- Employees
- 1,305
- P/E (TTM)
- 18.30
- P/B (TTM)
- 3.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
12
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$7.27 | $6.97 | +0.3010 | +4.32% |
|
Mar 2026 (Q1)
|
$5.82 | $7.01 | -1.1857 | -16.92% |
|
Dec 2025 (Q4)
|
$7.70 | $7.33 | +0.3703 | +5.05% |
|
Sep 2025 (Q3)
|
$7.16 | $7.33 | -0.1722 | -2.35% |
Financial Statements
| Revenues | $3.15B |
| Benefits Costs and Expenses | $1.58B |
| Cost Of Revenue | $437.20M |
| Costs And Expenses | $1.75B |
| Gross Profit | $2.72B |
| Nonoperating Income/Loss | $171.20M |
| Operating Expenses | $1.32B |
| Selling, General, and Administrative Expenses | $764.00M |
| Research and Development | $551.50M |
| Operating Income/Loss | $1.40B |
| Income/Loss From Continuing Operations After Tax | $1.31B |
| Income/Loss From Continuing Operations Before Tax | $1.57B |
| Income Tax Expense/Benefit | $262.10M |
| Income Tax Expense/Benefit, Deferred | $149.30M |
| Net Income/Loss | $1.31B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $1.31B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.31B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $30.23 |
| Diluted Earnings Per Share | $27.93 |
| Basic Average Shares | 42,300,000 |
| Diluted Average Shares | 45,900,000 |
| Assets | $7.22B |
| Current Assets | $3.48B |
| Inventory | $193.80M |
| Other Current Assets | $3.29B |
| Noncurrent Assets | $3.74B |
| Fixed Assets | $1.93B |
| Other Non-current Assets | $1.81B |
| Liabilities | $819.80M |
| Current Liabilities | $607.80M |
| Noncurrent Liabilities | $212.00M |
| Equity | $6.40B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.40B |
| Liabilities And Equity | $7.22B |
| Net Cash Flow From Operating Activities | $1.69B |
| Net Cash Flow From Operating Activities, Continuing | $1.69B |
| Net Cash Flow From Investing Activities | $744.50M |
| Net Cash Flow From Investing Activities, Continuing | $744.50M |
| Net Cash Flow From Financing Activities | -$2.22B |
| Net Cash Flow From Financing Activities, Continuing | -$2.22B |
| Net Cash Flow | $210.10M |
| Net Cash Flow, Continuing | $210.10M |
| Comprehensive Income/Loss | $1.29B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.29B |
| Other Comprehensive Income/Loss | $1.29B |
| Other Comprehensive Income/Loss Attributable To Parent | -$16.20M |